Metopocor (Metoprolol Tartrate)

Metoprolol tartrate is a selective β1‑adrenergic receptor antagonist. It blocks the action of catecholamines on β1 receptors in the heart, which decreases heart rate, myocardial contractility, and cardiac output. This results in reduced blood pressure and lower oxygen consumption by the heart muscle.

The dose of Metopocor is individualized by the prescribing clinician based on the patient’s specific condition, severity, response to therapy, and any comorbidities. Dosage adjustments may be required for renal or hepatic impairment, and the prescriber will set the appropriate infusion rate and duration.

Safety data for metoprolol tartrate in pregnancy and lactation are limited. It is generally classified as a drug of unknown risk, and use is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Consultation with a specialist is advised.

To order Metopocor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Metopocor (metoprolol tartrate) is a cardio‑selective β1‑blocker, offering a favorable profile for patients with respiratory disease compared with non‑selective agents. Its intravenous formulation allows rapid titration in acute settings, whereas oral beta blockers such as atenolol or propranolol are used for chronic management.

Metopocor should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Do not store at room temperature for extended periods, as stability may be compromised.

Metopocor is supplied as an injectable solution for intravenous use. It is typically administered by slow infusion under continuous cardiac monitoring, allowing the clinician to adjust the rate based on heart rate, blood pressure, and therapeutic response.

Serious adverse events include severe hypotension, bradycardia, heart block, bronchospasm (especially in patients with asthma or COPD), and allergic reactions such as rash or anaphylaxis. Prompt recognition and management of these events are essential, and patients should be monitored closely during infusion.

Metopocor is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and patients in cardiogenic shock. Caution is also advised in severe asthma, COPD, and uncontrolled heart failure.